Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
STO:CALTX
Watchlist
Price: 208 SEK 0.87% Market Closed
Market Cap: 12.5B SEK

Relative Value

The Relative Value of one CALTX stock under the Base Case scenario is 443.09 SEK. Compared to the current market price of 208 SEK, Calliditas Therapeutics AB is Undervalued by 53%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CALTX Relative Value
Base Case
443.09 SEK
Undervaluation 53%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
55
vs Industry
18
Median 3Y
7.8
Median 5Y
12.1
Industry
2.6
Forward
6.2
vs History
vs Industry
Median 3Y
-16.3
Median 5Y
-15.1
Industry
21.5
Forward
88.8
vs History
vs Industry
Median 3Y
-21.2
Median 5Y
-19.5
Industry
16.6
vs History
vs Industry
Median 3Y
-39.6
Median 5Y
-23.9
Industry
24
vs History
0
vs Industry
0
Median 3Y
16.6
Median 5Y
8.2
Industry
2.1
vs History
52
vs Industry
16
Median 3Y
7.9
Median 5Y
11.4
Industry
2.7
Forward
6.3
vs History
20
vs Industry
25
Median 3Y
8.4
Median 5Y
6.4
Industry
5.3
vs History
vs Industry
Median 3Y
-19.5
Median 5Y
-17.7
Industry
12.8
Forward
64.7
vs History
vs Industry
Median 3Y
-18.3
Median 5Y
-17.1
Industry
16.2
Forward
70.6
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-18.7
Industry
14.9
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-18.7
Industry
17.7
vs History
17
vs Industry
6
Median 3Y
10.2
Median 5Y
10.9
Industry
1.9

Multiples Across Competitors

CALTX Competitors Multiples
Calliditas Therapeutics AB Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Calliditas Therapeutics AB
STO:CALTX
12.5B SEK 7.8 -26 -35.9 -35.9
US
Eli Lilly and Co
NYSE:LLY
744B USD 15.2 67 36 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
362.6B USD 4.1 16.6 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.1 20.5 14.1 16.2
CH
Roche Holding AG
SIX:ROG
206.1B CHF 3.4 24.9 9.4 10.9
CH
Novartis AG
SIX:NOVN
186.1B CHF 4.3 17.7 10.4 14
UK
AstraZeneca PLC
LSE:AZN
163.6B GBP 4 28.3 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
199.5B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
135.8B USD 2.2 17.2 7.4 10.4
P/E Multiple
Earnings Growth PEG
SE
Calliditas Therapeutics AB
STO:CALTX
Average P/E: 25.4
Negative Multiple: -26
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.6
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.9
32%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.2
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Calliditas Therapeutics AB
STO:CALTX
Average EV/EBITDA: 433.6
Negative Multiple: -35.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Calliditas Therapeutics AB
STO:CALTX
Average EV/EBIT: 1 867.2
Negative Multiple: -35.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
16.2
14%
1.2
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
10%
1